AI assistant
Sending…
Gossamer Bio, Inc. — Director's Dealing 2021
Oct 26, 2021
32603_dirs_2021-10-26_fa011de0-b28e-4fcc-a3fd-4b96f5b98b33.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2021-10-25
Reporting Person: Aranda Richard (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-25 | Common Stock | S | 2377 | $12.25 | Disposed | 217432 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2539 | Indirect |
Footnotes
F1: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
More from Gossamer Bio, Inc.
Proxy Solicitation & Information Statement
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 27
Major Shareholding Notification
2026
Mar 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20